Analysts Set Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Price Target at $32.60

Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) have earned an average recommendation of “Hold” from the six ratings firms that are currently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $32.60.

SLN has been the topic of several recent analyst reports. Wall Street Zen upgraded shares of Silence Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Thursday, January 22nd.

Silence Therapeutics Trading Down 2.0%

Silence Therapeutics stock opened at $4.45 on Thursday. The company has a fifty day simple moving average of $5.62 and a 200-day simple moving average of $5.79. Silence Therapeutics has a 12-month low of $1.97 and a 12-month high of $7.78. The stock has a market cap of $210.17 million, a P/E ratio of -3.30 and a beta of 1.34.

Institutional Investors Weigh In On Silence Therapeutics

A number of hedge funds have recently modified their holdings of SLN. Nantahala Capital Management LLC increased its position in Silence Therapeutics by 48.0% during the fourth quarter. Nantahala Capital Management LLC now owns 1,542,427 shares of the company’s stock worth $9,378,000 after buying an additional 500,000 shares during the last quarter. Marshall Wace LLP increased its holdings in Silence Therapeutics by 87.1% in the 4th quarter. Marshall Wace LLP now owns 155,680 shares of the company’s stock worth $947,000 after purchasing an additional 72,461 shares in the last quarter. Jane Street Group LLC bought a new stake in Silence Therapeutics during the fourth quarter valued at $177,000. Bank of Montreal Can grew its position in Silence Therapeutics by 4.4% in the 4th quarter. Bank of Montreal Can now owns 160,474 shares of the company’s stock valued at $976,000 after purchasing an additional 6,692 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Silence Therapeutics by 65.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,653 shares of the company’s stock valued at $83,000 after acquiring an additional 5,421 shares in the last quarter. Institutional investors and hedge funds own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.